di-tert-butyl diisopropylphosphoramidite

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磷酸及其衍生物
• 英文名称: di-tert-butyl diisopropylphosphoramidite
• 英文别名: di-tert-butyl N,N-diisopropylphosphoramidite；Di-tert-butyl diisopropylphosphoramidate；N-[bis[(2-methylpropan-2-yl)oxy]phosphoryl]-N-propan-2-ylpropan-2-amine
• 化学式: C₁₄H₃₂NO₃P
• 分子量: 293.387
• InChiKey: HQNWZXVJHYLMAU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  di-tert-butyl diisopropylphosphoramidite 在 四氮唑 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.5h， 生成 di(tert-butyl) 2-({2-[(2-chloroethyl)(2-hydroxyethyl)amino]-3,5-dinitrobenzoyl}amino)ethyl phosphate
  参考文献：
  名称：

  Synthesis of asymmetric halomesylate mustards with aziridineethanol/alkali metal halides: application to an improved synthesis of the hypoxia prodrug PR-104

  摘要：

  Aromatic asymmetric halomesylate mustards are efficiently prepared by reaction of activated aromatic chlorides with aziridine-ethanol/alkali metal halides, followed by mesylation of the haloalcohol. The reaction conditions are sufficiently mild to be compatible with a range of different substituents and protecting groups, including carboxylate and phosphate esters, and have been used in an improved synthesis of the anticancer bromomesylate mustard PR-104, now in clinical trials. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2007.04.044

文献信息

• PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
  申请人：ANDERSON MARK B.

  公开号：US20100068197A1

  公开（公告）日：2010-03-18

  Disclosed are compounds of Formula I effective as cytotoxic agents. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  揭示的是作为细胞毒性剂有效的I式化合物。本发明的化合物在治疗多种临床病况中是有用的，这些病况中发生异常细胞的不受控制的生长和扩散。
• [EN] LXR AGONISTS AND USES THEREOF<br/>[FR] AGONISTES DU RÉCEPTEUR X DU FOIE ET LEURS UTILISATIONS
  申请人：RGENIX INC

  公开号：WO2015106164A1

  公开（公告）日：2015-07-16

  This invention features compounds that modulate the activity of liver X receptors, pharmaceutical compositions including the compounds of the invention, and methods of utilizing those compositions for modulating the activity of liver X receptors in the treatment of cancer.

  这项发明涉及调节肝X受体活性的化合物，包括该发明的化合物的药物组合物，以及利用这些组合物调节肝X受体活性以治疗癌症的方法。
• LPA receptor agonists and antagonists and methods of use
  申请人：——

  公开号：US20030130237A1

  公开（公告）日：2003-07-10

  The present invention relates to compounds according to formula (I) as disclosed herein as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating cancer, enhancing cell proliferation, treating a wound, treating apoptosis or preserving or restoring function in a cell, tissue, or organ, culturing cells, preserving organ or tissue function, and treating a dermatological condition.

  本发明涉及根据所述的化合物的化学式(I)，以及包括这些化合物的药物组合物。还公开了使用这些化合物的方法，这些方法具有作为LPA受体的激动剂或拮抗剂的活性；这些方法包括抑制LPA对LPA受体的活性，调节LPA受体的活性，治疗癌症，增强细胞增殖，治疗伤口，治疗凋亡或保护或恢复细胞、组织或器官的功能，培养细胞，保护器官或组织功能，以及治疗皮肤病症。
• Spiro-1-benzofuranpiperidinylalkanoic acids as a novel and selective sphingosine S1P5 receptor agonist chemotype
  作者：Axel R. Stoit、Jos H.M. Lange、Hein K.A.C. Coolen、Annemieke Rensink、Adri van den Hoogenband、Arnold P. den Hartog、Sjoerd van Schaik、Chris G. Kruse

  DOI：10.1016/j.bmcl.2017.12.018

  日期：2018.2

  The synthesis and SAR of a novel class of spirobenzofuranpiperidinyl-derived alkanoic acids 6–34 as sphingosine S1P5 receptor agonists are described. The target compounds generally elicit high S1P5 receptor agonistic potencies and in general are selective against both S1P1 and S1P3 receptor subtypes. The key compound 32 shows a high bioavailability of 73% and a CNS/plasma ratio of 0.8 after oral administration

  描述了一类新的由螺苯并呋喃哌啶基衍生的链烷酸6 – 34作为鞘氨醇S1P 5受体激动剂的合成和SAR 。靶标化合物通常引起高的S1P 5受体激动作用，并且通常对S1P 1和S1P 3受体亚型具有选择性。在大鼠中口服给药后，关键化合物32显示出73％的高生物利用度和0.8的CNS /血浆比率。
• Acetal phosphate-derived LPA mimics, PPARgamma activators, and autotaxin inhibitors
  申请人：Miller D. Duane

  公开号：US20060270634A1

  公开（公告）日：2006-11-30

  Disclosed are compositions that modulate the effects of extracellular LPA receptors, the intracellular PPARγ receptor, and autotaxin, and methods for their use.

  揭示了调节细胞外LPA受体、细胞内PPARγ受体和自体脂肪酶效应的组合物，以及它们的使用方法。